CoChat
Sign Up
Cited by 302Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular PreventionCardiac Imaging and Diagnostics

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease

Open access
Lloyd-Jones, Donald M., Braun, Lynne T., Ndumele, Chiadi E., Smith, Sidney C., Sperling, Laurence S., Virani, Salim S., Blumenthal, Roger S.·2019·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2018.11.005
Open this paper in CoChat — free account

Abstract

Risk assessment is a critical step in the current approach to primary prevention of atherosclerotic cardiovascular disease. Knowledge of the 10-year risk for atherosclerotic cardiovascular disease identifies patients in higher-risk groups who are likely to have greater net benefit and lower number needed to treat for both statins and antihypertensive therapy. Current U.S. prevention guidelines for blood pressure and cholesterol management recommend use of the pooled cohort equations to start a process of shared decision-making between clinicians and patients in primary prevention. The pooled cohort equations have been widely validated and are broadly useful for the general U.S. clinical population. But, they may systematically underestimate risk in patients from certain racial/ethnic groups, those with lower socioeconomic status or with chronic inflammatory diseases, and overestimate risk in patients with higher socioeconomic status or who have been closely engaged with preventive healthcare services. If uncertainty remains for patients at borderline or intermediate risk, or if the patient is undecided after a patient-clinician discussion with consideration of risk enhancing factors (e.g., family history), additional testing with measurement of coronary artery calcium can be useful to reclassify risk estimates and improve selection of patients for use or avoidance of statin therapy. This special report summarizes the rationale and evidence base for quantitative risk assessment, reviews strengths and limitations of existing risk scores, discusses approaches for refining individual risk estimates for patients, and provides practical advice regarding implementation of risk assessment and decision-making strategies in clinical practice.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.11.005

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 84 references

Research works printed but not linked: 2

  1. Fuster, 1996, 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, J Am Coll Cardiol, 27, 957
  2. DeFilippis, 2017, Eur Heart, 38, 598

Cited by

Sorted by citations

Items 201–300 of 301

Related

See all

Metadata

Authors
Lloyd-Jones, D. M., Braun, L. T., Ndumele, C. E., Smith, S. C., Sperling, L. S., Virani, S. S., & Blumenthal, R. S.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-06
Volume
73
Issue
24
Pages
3153-3167
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2018.11.005
OpenAlex
W3137768417
Cited by
302
References
84
Citations by year
2026: 25 · 2025: 54 · 2024: 40 · 2023: 43 · 2022: 44 · 2021: 41 · 2020: 28 · 2019: 26
FWCI
25.12
Type
journal article
Language
en
Update notices
erratum (2019-06-25)
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
Keywords
atherosclerotic cardiovascular disease, primary prevention, quantitative risk assessment, Pooled Cohort Equations, shared decision-making, statin therapy, antihypertensive therapy, coronary artery calcium, risk reclassification, racial and ethnic disparities, socioeconomic status, chronic inflammatory diseases, family history (medicine), blood pressure control, cholesterol management
MeSH terms
Clinical Decision-Making, Decision Making, Shared, Coronary Artery Disease, Female, Humans, Male, Middle Aged, Practice Patterns, Physicians', Primary Prevention, Risk Factors, United States, Risk Assessment, Quality Improvement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review